As well as increased tumor trafficking activity, we demonstrated that the co-introduced CCR2-CCL2 axis might also be advantageous for potentiating target-responsive cytocidal activity, i.e., WT1-specific TCR-mediated anti-lung cancer reactivity. The gene discussed is CCR2; the disease is lung carcinoma.